Document is current
Any future updates will be listed below
-
Authors
Sandner, Amelie
Udovica, Simon
Ferner, Muna
Marhold, Maximilian
Strasser-Weippl, Kathrin
Bartsch, Rupert https://orcid.org/0000-0002-4384-6917
-
Funding
Funding for this research was provided by:
Medical University of Vienna
- License Information
-
More Information
Article History
Received: 12 January 2026
Accepted: 12 January 2026
First Online: 2 February 2026
Conflict of interest
: A. Sandner: Travel support: Roche, Pfizer. S. Udovica: Advisory Role: Johnson & Johnson, Amgen; Oncopeptides. Lecture Honoraria: Novartis, Servier, Eli-Lilly, Gilead, MedMedia; Travel support: AbbVie, AOP-Orphan, Beigene, Daiichi-Sankyo, GlaxoSmithKline, Johnson & Johnson, Eli-Lilly, Pfizer, Roche, Servier, Stemline. M. Ferner: Travel support: Roche, Pfizer, Daiichi Sankyo, Novartis. Speaker Roles: Gilead, MSD. M. Marhold: Lectures, advisory board participation and consultation: Roche, Eli Lilly, Novartis, Astra Zeneca, Daiichi Sankyo, Pfizer, MSD, Gilead, and Medmedia. Travel support: Amgen, Gilead, Roche, Novartis, Pierre Fabre, Daiichi Sankyo, and Eisai. K. Strasser-Weippl: Advisory Boards: Roche, Pfizer, Novartis, Lilly, Daiichi, Myriad, Seagen, MSD, Astra Zeneca. Travel support: Roche, Pfizer, MSD. R. Bartsch has received honoraria from Amgen, Astra-Zeneca, BMS, Daichi, Eisai, Eli-Lilly, Gilead, Gruenenthal, MSD, MedMedia, Novartis, Pfizer, Pierre-Fabre, Roche, Seagen, Stemline, research support from Daiichi, and travel support from Astra-Zeneca, Daiichi, Ely-Lilly, MSD, and Novartis.
